Kris P. Croome, M.D.

Closed for Enrollment

• Fenofibrate to prevent Ischemic Cholangiopathy in Donation after Circulatory Death liver transplantation (FICsDCD) (FICsDCD) Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

  The purpose of this study is to test the tolerability, safety, and effectiveness of 12 weeks once-daily fenofibrate in reducing Ischemic Cholangiopathy (IC) incidence after Donation after Circulatory Death (DCD) liver transplantation. Additionally to assess the association between serum markers of cholestasis and development of IC. Tolerability and safety will be assessed as proportions of: drug discontinuation, and new grade 3 or 4 adverse events. Effectiveness will be assessed as incidence of cholangiographically-diagnosed IC and incidence of any IC-related complication.

• The TOGETHER Project - Transplant Organ Genomics to Help Prevent Rejection in Liver Transplant Recipients Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

  The purpose of this study is to validate the use of a RNAseq-based peripheral blood assay in liver transplant recipients when correlated to liver biopsy results.